Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. It has a research collaboration with Keck School of Medicine of University of Southern California using pelareorep in combination with Keytruda, Velcade, and dexamethasone to treat multiple myeloma; and a clinical collaboration with SOLTI breast cancer research. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone403-670-7377
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/13/2020 (Estimated)
OptionableNot Optionable
Oncolytics Biotech (NASDAQ:ONCY) Frequently Asked Questions
What is Oncolytics Biotech's stock symbol?
Oncolytics Biotech trades on the NASDAQ under the ticker symbol "ONCY."
How were Oncolytics Biotech's earnings last quarter?
Oncolytics Biotech, Inc. (NASDAQ:ONCY) announced its earnings results on Friday, August, 3rd. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by $0.25. View Oncolytics Biotech's Earnings History.
When is Oncolytics Biotech's next earnings date?
What price target have analysts set for ONCY?
1 brokerages have issued twelve-month target prices for Oncolytics Biotech's shares. Their forecasts range from $9.00 to $9.00. On average, they expect Oncolytics Biotech's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 255.7% from the stock's current price. View Analyst Price Targets for Oncolytics Biotech.
What is the consensus analysts' recommendation for Oncolytics Biotech?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oncolytics Biotech.
Has Oncolytics Biotech been receiving favorable news coverage?
Media stories about ONCY stock have trended negative on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Oncolytics Biotech earned a news impact score of -2.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the company's share price in the next several days. View News Stories for Oncolytics Biotech.
Are investors shorting Oncolytics Biotech?
Oncolytics Biotech saw a decline in short interest during the month of January. As of January 31st, there was short interest totalling 1,560,000 shares, a decline of 10.3% from the January 15th total of 1,740,000 shares. Based on an average trading volume of 1,670,000 shares, the days-to-cover ratio is presently 0.9 days. Currently, 6.0% of the company's shares are short sold. View Oncolytics Biotech's Current Options Chain.
Who are some of Oncolytics Biotech's key competitors?
Some companies that are related to Oncolytics Biotech include Evolus (EOLS), Concert Pharmaceuticals (CNCE), CytomX Therapeutics (CTMX), Spectrum Pharmaceuticals (SPPI), Albireo Pharma (ALBO), Lexicon Pharmaceuticals (LXRX), OptiNose (OPTN), MannKind (MNKD), AMAG Pharmaceuticals (AMAG), Kamada (KMDA), Wave Life Sciences (WVE), VBI Vaccines (VBIV), Aduro BioTech (ADRO), Osmotica Pharmaceuticals (OSMT) and Kalvista Pharmaceuticals (KALV).
What other stocks do shareholders of Oncolytics Biotech own?
Who are Oncolytics Biotech's key executives?
Oncolytics Biotech's management team includes the folowing people:
- Dr. Matthew C. Coffey, Pres, CEO & Director
- Mr. Kirk J. Look, Chief Financial Officer
- Mr. Michael Moore, VP of Investor Relations & Corp. Communications
- Dr. Rita Laeufle, Chief Medical Officer
- Mr. Andrew R. de Guttadauro, Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc (Age 52)
Who are Oncolytics Biotech's major shareholders?
Oncolytics Biotech's stock is owned by a variety of of institutional and retail investors. Top institutional investors include CIBC World Markets Inc. (0.05%), Jane Street Group LLC (0.05%), Crescent Grove Advisors LLC (0.03%), Ladenburg Thalmann Financial Services Inc. (0.03%) and Cedar Mountain Advisors LLC (0.02%).
Which major investors are buying Oncolytics Biotech stock?
ONCY stock was acquired by a variety of institutional investors in the last quarter, including CIBC World Markets Inc., Jane Street Group LLC, Crescent Grove Advisors LLC, Ladenburg Thalmann Financial Services Inc. and Cedar Mountain Advisors LLC.
How do I buy shares of Oncolytics Biotech?
Shares of ONCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Oncolytics Biotech's stock price today?
One share of ONCY stock can currently be purchased for approximately $2.53.
How big of a company is Oncolytics Biotech?
What is Oncolytics Biotech's official website?
How can I contact Oncolytics Biotech?
Oncolytics Biotech's mailing address is 1167 Kensington Crescent Suite 210, Calgary A0, T2N 1X7. The company can be reached via phone at 403-670-7377 or via email at [email protected]
MarketBeat Community Rating for Oncolytics Biotech (NASDAQ ONCY)
MarketBeat's community ratings are surveys of what our community members think about Oncolytics Biotech and other stocks. Vote "Outperform" if you believe ONCY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCY will underperform the S&P 500 over the long term. You may vote once every thirty days.
